Canadian Journal of Pain
November 8, 2024
Jiwon Lee, Kaylyssa Philip, Hance Clarke et al.
3 citations
A proposed clinical trial design for psilocybin as a treatment for neuropathic pain, called the PEACE-PAIN trial, is supported by patient survey responses but could be improved by adding detailed discussions of the existing evidence on efficacy, safety, tolerability, and management of adverse effects. The finding that individuals with prior psychedelic use are interested in participating has important implications for the trial's inclusion and exclusion criteria.
JMIR research protocols
April 17, 2024
Akash Goel, Bhavya Kapoor, Hillary Chan et al.
2 citations
Chronic pain affects about 8 million Canadians (20%) and costs the healthcare system over US $60 billion yearly. This paper describes the planned protocol for a pilot randomized controlled trial testing three treatments: intravenous ketamine alone, cognitive behavioral therapy with mindfulness meditation (CBT/MM), or a combination of both. The primary goal is to assess feasibility—recruitment, consent, withdrawal, adherence, missing data, and adverse events—in 30 participants over 20 weeks. Secondary outcomes include changes in pain intensity and pain interference at week 20. Recruitment had not started as of November 2023; the study is expected to complete by December 2025. Results will inform a larger trial.
PloS one
January 1, 2024
Karim S Ladha, Jiwon Lee, Gabriella F Mattina et al.
A pilot trial will test whether weekly inhaled nitrous oxide is feasible and preliminarily effective for treatment-resistant depression compared with the active placebo midazolam. Forty participants will receive either nitrous oxide (1 hour at 50% concentration) plus intravenous saline or oxygen (1 hour at 50% concentration) plus intravenous midazolam once per week for 4 weeks, with 6 weeks of follow-up. Feasibility will be assessed by recruitment and withdrawal rates, adherence, missing data, and adverse events. The main exploratory clinical outcome is change in depression scores at day 42. Results will guide a future definitive trial.